NPPA fixes price of 17 formulations including BP drugs,painkillers; details
New Delhi : Through a recent notice, the National Pharmaceutical Pricing Authority,Ministry of Chemicals and Fertilizers,Government of India has fixed prices of 17 formulations.
These include some popular BP medications, painkillers, diabetes drugs by many prominent manufacturers including Sun Pharma,Themis Pharmaceuticals,mankind pharma and much more
The move comes In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers. The National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), has fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
|
|
|
|
|
|
(1) | (2) | (3) | (4) | (5) | (6) |
1. | Glimepiride + Metformin Tablet | Each uncoated bilayered tablet contains: Glimepiride IP 1mg Metformin Hydrochloride IP 500mg (as prolonged-release form) |
1 Tablet | M/s Swiss Garnier Genexiaa Sciences Pvt. Ltd. / M/s Apex Laboratories Pvt. Ltd. | 4.95 |
2. | Glimepiride + Metformin Tablet | Each uncoated bilayered tablet contains: Glimepiride IP 2mg Metformin Hydrochloride IP 500mg (as prolonged-release form) |
1 Tablet | M/s Swiss Garnier Genexiaa Sciences Pvt. Ltd. / M/s Apex Laboratories Pvt. Ltd. | 7.98 |
3. | Telmisartan + Chlorthalidone Tablet | Each uncoated bilayered tablet contains: Telmisartan IP 80mg Chlorthalidone IP 12.5mg |
1 Tablet | M/s Windlas Biotech Pvt. Ltd. / M/s Mankind Pharma Limited | 13.82 |
4. | Escitalopram Tablet | Each film coated tablet contains: Escitalopram Oxalate eq. to Escitalopram 15mg |
1 Tablet | M/s Sun Pharma Laboratories Limited | 10.68 |
5. | Aceclofenac + Paracetamol Tablet (Mytigesic Plus) | Each uncoated tablet contains: Aceclofenac IP 100mg Paracetamol IP 325mg |
1 Tablet | M/s Themis Pharmaceuticals | 3.04 |
6. | Diclofenac + Paracetamol Tablet (Inflamase Plus) | Each uncoated tablet contains: Diclofenac Sodium IP 50mg (Enteric coated Granules) Paracetamol IP 325mg |
1 Tablet |
M/s Themis Pharmaceuticals | 2.782 |
7. | Clopidogrel Tablet | Each Film coated tablet contains: Clopidogrel Bisulphate IP eq. to Clopidogrel 150mg |
1 Tablet | M/s Windlas Biotech Pvt. Ltd. / M/s Mankind Pharma Limited | 6.25 |
8. | Metoprolol Tablet | Each Film coated extended release tablet contains: Metoprolol Succinate IP 11.875mg eq. to Metoprolol Tartrate 12.5mg |
1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Mankind Pharma Limited | 3.03 |
9. | Rosuvastatin + Clopidogrel Capsule | Each Hard Gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (as film coated Rosuvastatin tablet), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (as two film coated Clopidogrel tablet each containing clopidogrel 37.5mg)
|
1 Capsule |
M/s Windlas Biotech Pvt. Ltd. / M/s Mankind Pharma Limited | 12.95 |
10. | Rosuvastatin + Clopidogrel Capsule | Each Hard Gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (as film coated Rosuvastatin tablet), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (as two film coated Clopidogrel tablet each containing clopidogrel 37.5mg) |
1 Capsule |
M/s Windlas Biotech Pvt. Ltd. / M/s Mankind Pharma Limited | 16.06 |
11. | Telmisartan + Cilnidipine Tablet | Each film coated tablet contains: Telmisartan IP 40mg, Cilnidipine IP 10mg |
1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cipla Ltd. | 8.19 |
12. | Telmisartan + Cilnidipine Tablet | Each film coated tablet contains: Telmisartan IP 80mg, Cilnidipine IP 10mg |
1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cipla Ltd. | 13.48 |
13. | Paracetamol Tablet | Each uncoated bilayer tablet contains: Paracetamol IP 300mg (As immediate release) Paracetamol IP 700mg (As sustained release) |
1 Tablet |
M/s Surien Pharmaceuticals (P) Ltd. / M/s Geno Pharmaceuticals Pvt. Ltd. | 3.38 |
14. | Amoxycillin + Potassium Clavulanate Dry Syrup (Genomox-CV Forte ) | Each 5ml of reconstituted suspension contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 400mg, Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 57mg |
1 ml |
M/s Medicef Pharma / M/s Geno Pharmaceuticals Pvt. Ltd. | 3.27 |
15. | Dextromethorpran Hydrobromide + Chlorpheniramine Maleate Syrup | Each 5ml Syrup contains: Dextromethorpran Hydrobromide IP 10mg Chlorpheniramine Maleate IP 2mg |
1 ml |
M/s Zydus Healthcare Limited | 0.57 |
16. | Dextromethorpran Hydrobromide + Chlorpheniramine Maleate Syrup | Each 5ml Syrup contains: Dextromethorpran Hydrobromide IP 10mg Chlorpheniramine Maleate IP 5mg |
1 ml |
M/s Zydus Healthcare Limited | 0.74 |
17. | Paracetamol + Phenylephrine HCl + Diphenhydramine HCl + Caffeine Tablet | Each uncoated tablet contains: Paracetamol IP 500mg, Phenylephrine HCl IP 5mgDiphenhydramine HCl IP 25mg, Caffeine (anhydrous) IP 30mg |
1 Tablet |
M/s Shiv Industries / M/s Profic Organic Limited | 3.36 |
Note:
(a) The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above
i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant
statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
For more details check out the notice below
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd